We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Book Review |

The Legacy of Tracy J. Putnam and H. Houston Merritt: Modern Neurology in the United States

Arch Neurol. 2009;66(3):415. doi:10.1001/archneurol.2009.34.
Text Size: A A A
Published online


Notable partnerships in medicine and science have included Hubel and Wiesel, Watson and Crick, Jacob and Monod, Jasper and Penfield, and Kety and Schmidt, among others. Their joint efforts were synergistic and mutually beneficial. Their combined careers allowed both to prosper and brought esteem by colleagues that was equally shared. Rowland describes vividly the partnership of Putnam and Merritt in their research in 1938 to develop the anticonvulsant diphenylhydantoin (now phenytoin) with the trade name Dilantin (Pfizer, New York, New York). The scientific achievement of Putnam and Merritt is monumental, as diphenylhydantoin has proved to be a major contribution to combat epilepsy. Their personal outcomes, however, were in stark contrast compared with other scientific partnerships and the reasons and facts for this disparity, as provided by Rowland in graphic style, is a story of Shakespearean proportion. The real story conveyed by Rowland is the personal and professional lives and relationships between the two men. Rowland knows the full story because he was there at Columbia and the Neurological Institute for most of it. He never knew Putnam personally but has meticulously reviewed the archives of the medical school and Presbyterian Hospital to obtain the essential facts and the flavor of the times. He did know Merritt well from 1950 until Merritt died in 1979.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.